Plasma biomarkers for mild cognitive impairment and Alzheimer's disease

Brain Research Reviews

Volumn 61, Issue 2, 2009, Pages 69-80

  Song, Fei ^a,b   Poljak, Anne ^b   Smythe, George A ^b   Sachdev, Perminder ^a,b  

^a PRINCE OF WALES HOSPITAL   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Alzheimer's disease; Amyloid beta; Biomarker; Mild cognitive impairment; Plasma; Proteomics

Indexed keywords

ALPHA 1 ANTITRYPSIN; ALPHA 2 MACROGLOBULIN; AMYLOID BETA PROTEIN; AMYLOID BETA PROTEIN[1-40]; AMYLOID BETA PROTEIN[1-42]; APOLIPOPROTEIN A1; APOLIPOPROTEIN B100; APOLIPOPROTEIN E; APOLIPOPROTEIN E4; CHOLESTEROL; CLUSTERIN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; COMPLEMENT FACTOR H; DESMOPLAKIN; GALECTIN 7; HEMOGLOBIN ALPHA CHAIN; HEMOPEXIN; HISTONE H2B; HOMOCYSTEINE; INTERLEUKIN 1; MALONALDEHYDE; OROSOMUCOID; PLACEBO; PREALBUMIN; ROSIGLITAZONE; TRANSFERRIN; UNINDEXED DRUG; VALPROATE SEMISODIUM; VITAMIN D BINDING PROTEIN;

ALZHEIMER DISEASE; CLINICAL TRIAL; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE MARKER; DRUG EFFICACY; DRUG MECHANISM; EARLY DIAGNOSIS; HUMAN; INFLAMMATION; LIPOPROTEIN METABOLISM; MILD COGNITIVE IMPAIRMENT; NEUROFIBRILLARY TANGLE; OXIDATIVE STRESS; PARKINSON DISEASE; PREDICTION; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEOMICS; REVIEW; SENILE PLAQUE; SENSITIVITY AND SPECIFICITY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; BIOLOGICAL MARKERS; COGNITION DISORDERS; HUMANS; LIPOPROTEINS; OXIDATIVE STRESS; PROTEOMICS;

EID: 70349499185     PISSN: 01650173     EISSN: 18726321     Source Type: Journal    
DOI: 10.1016/j.brainresrev.2009.05.003     Document Type: Review

References (107)

1. Ait-ghezala G., Abdullah L., Volmar C.H., Paris D., Luis C.A., Quadros A., Mouzon B., Mullan M.A., Keegan A.P., Parrish J., Crawford F.C., Mathura V.S., and Mullan M.J. Diagnostic utility of APOE, soluble CD40, CD40L, and Abeta1-40 levels in plasma in Alzheimer's disease. Cytokine 44 (2008) 283-287
2. Akiyama H., Barger S., Barnum S., Bradt B., Bauer J., Cole G.M., Cooper N.R., Eikelenboom P., Emmerling M., Fiebich B.L., Finch C.E., Frautschy S., Griffin W.S., Hampel H., Hull M., Landreth G., Lue L., Mrak R., Mackenzie I.R., McGeer P.L., O'Banion M.K., Pachter J., Pasinetti G., Plata-Salaman C., Rogers J., Rydel R., Shen Y., Streit W., Strohmeyer R., Tooyoma I., Van Muiswinkel F.L., Veerhuis R., Walker D., Webster S., Wegrzyniak B., Wenk G., and Wyss-Coray T. Inflammation and Alzheimer's disease. Neurobiol. Aging 21 (2000) 383-421
3. Akuffo E.L., Davis J.B., Fox S.M., Gloger I.S., Hosford D., Kinsey E.E., Jones N.A., Nock C.M., Roses A.D., Saunders A.M., Skehel J.M., Smith M.A., and Cutler P. The discovery and early validation of novel plasma biomarkers in mild-to-moderate Alzheimer's disease patients responding to treatment with rosiglitazone. Biomarkers 13 (2008) 618-636
4. Albert M., Blacker D., Moss M.B., Tanzi R., and McArdle J.J. Longitudinal change in cognitive performance among individuals with mild cognitive impairment. Neuropsychology 21 (2007) 158-169
5. Andreasen N., Minthon L., Davidsson P., Vanmechelen E., Vanderstichele H., Winblad B., and Blennow K. Evaluation of CSF-tau and CSF-Abeta42 as diagnostic markers for Alzheimer disease in clinical practice. Arch. Neurol. 58 (2001) 373-379
6. Bauer J., Strauss S., Schreiter-Gasser U., Ganter U., Schlegel P., Witt I., Yolk B., and Berger M. Interleukin-6 and alpha-2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices. FEBS Lett. 285 (1991) 111-114
7. Biere A.L., Ostaszewski B., Stimson E.R., Hyman B.T., Maggio J.E., and Selkoe D.J. Amyloid beta-peptide is transported on lipoproteins and albumin in human plasma. J. Biol. Chem. 271 (1996) 32916-32922
8. Blacker D., Lee H., Muzikansky A., Martin E.C., Tanzi R., McArdle J.J., Moss M., and Albert M. Neuropsychological measures in normal individuals that predict subsequent cognitive decline. Arch. Neurol. 64 (2007) 862-871
9. Blasko I., Jellinger K., Kemmler G., Krampla W., Jungwirth S., Wichart I., Tragl K.H., and Fischer P. Conversion from cognitive health to mild cognitive impairment and Alzheimer's disease: prediction by plasma amyloid beta 42, medial temporal lobe atrophy and homocysteine. Neurobiol. Aging 29 (2008) 1-11
10. Boyle P.A., Wilson R.S., Aggarwal N.T., Tang Y., and Bennett D.A. Mild cognitive impairment: risk of Alzheimer disease and rate of cognitive decline. Neurology 67 (2006) 441-445
11. Chen M., Inestrosa N.C., Ross G.S., and Fernandez H.L. Platelets are the primary source of amyloid beta-peptide in human blood. Biochem. Biophys. Res. Commun. 213 (1995) 96-103
12. Choi J., Malakowsky C.A., Talent J.M., Conrad C.C., and Gracy R.W. Identification of oxidized plasma proteins in Alzheimer's disease. Biochem. Biophys. Res. Commun. 293 (2002) 1566-1570
13. Corder E.H., Saunders A.M., Risch N.J., Strittmatter W.J., Schmechel D.E., Gaskell Jr. P.C., Rimmler J.B., Locke P.A., Conneally P.M., Schmader K.E., et al. Protective effect of apolipoprotein E type 2 allele for late onset Alzheimer disease. Nat. Genet. 7 (1994) 180-184
14. Cutler P., Akuffo E., Briggs D., Bodnar W., Debouck C., Fox S., Bibson R., Gormley D., Holbrook J., Hunter A., Kinsey E., Prinjha R., Richardson J., Roses A., Smith M., Tsokanas N., Wille D., Wu W., Yates J., and Gloger I. Proteomic identification and early validation of complement 1 inhibitor and pigment epithelium-derived factor: two novel biomarkers of Alzheimer's disease in human plasma. Proteomics Clin. Appl. 2 (2008) 467-477
15. Davidsson P., and Sjogren M. Proteome studies of CSF in AD patients. Mech. Ageing Dev. 127 (2006) 133-137
16. Dik M.G., Jonker C., Hack C.E., Smit J.H., Comijs H.C., and Eikelenboom P. Serum inflammatory proteins and cognitive decline in older persons. Neurology 64 (2005) 1371-1377
17. Engelhart M.J., Geerlings M.I., Meijer J., Kiliaan A., Ruitenberg A., van Swieten J.C., Stijnen T., Hofman A., Witteman J.C., and Breteler M.M. Inflammatory proteins in plasma and the risk of dementia: the rotterdam study. Arch. Neurol. 61 (2004) 668-672
18. Farlow M.R., He Y., Tekin S., Xu J., Lane R., and Charles H.C. Impact of APOE in mild cognitive impairment. Neurology 63 (2004) 1898-1901
19. Ferri C.P., Prince M., Brayne C., Brodaty H., Fratiglioni L., Ganguli M., Hall K., Hasegawa K., Hendrie H., Huang Y., Jorm A., Mathers C., Menezes P.R., Rimmer E., and Scazufca M. Global prevalence of dementia: a Delphi consensus study. Lancet 366 (2005) 2112-2117
20. Frank R.A., Galasko D., Hampel H., Hardy J., de Leon M.J., Mehta P.D., Rogers J., Siemers E., and Trojanowski J.Q. Biological markers for therapeutic trials in Alzheimer's disease. Proceedings of the biological markers working group; NIA initiative on neuroimaging in Alzheimer's disease. Neurobiol. Aging 24 (2003) 521-536
21. Fukumoto H., Tennis M., Locascio J.J., Hyman B.T., Growdon J.H., and Irizarry M.C. Age but not diagnosis is the main predictor of plasma amyloid beta-protein levels. Arch. Neurol. 60 (2003) 958-964
22. Gabryelewicz T., Styczynska M., Luczywek E., Barczak A., Pfeffer A., Androsiuk W., Chodakowska-Zebrowska M., Wasiak B., Peplonska B., and Barcikowska M. The rate of conversion of mild cognitive impairment to dementia: predictive role of depression. Int. J. Geriatr. Psychiatry 22 (2007) 563-567
23. Ganguli M., Dodge H.H., Shen C., and DeKosky S.T. Mild cognitive impairment, amnestic type: an epidemiologic study. Neurology 63 (2004) 115-121
24. Gasque P., Dean Y.D., McGreal E.P., VanBeek J., and Morgan B.P. Complement components of the innate immune system in health and disease in the CNS. Immunopharmacology 49 (2000) 171-186
25. German D.C., Gurnani P., Nandi A., Garner H.R., Fisher W., Diaz-Arrastia R., O'Suilleabhain P., and Rosenblatt K.P. Serum biomarkers for Alzheimer's disease: proteomic discovery. Biomed. Pharmacother. 61 (2007) 383-389
26. Ghiso J., Shayo M., Calero M., Ng D., Tomidokoro Y., Gandy S., Rostagno A., and Frangione B. Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J. Biol. Chem. 279 (2004) 45897-45908
27. Gloeckner S.F., Meyne F., Wagner F., Heinemann U., Krasnianski A., Meissner B., and Zerr I. Quantitative analysis of transthyretin, tau and amyloid-beta in patients with dementia. J. Alzheimers Dis. 14 (2008) 17-25
28. Gollin P.A., Kalaria R.N., Eikelenboom P., Rozemuller A., and Perry G. Alpha 1-antitrypsin and alpha 1-antichymotrypsin are in the lesions of Alzheimer's disease. Neuroreport 3 (1992) 201-203
29. Graff-Radford N.R., Crook J.E., Lucas J., Boeve B.F., Knopman D.S., Ivnik R.J., Smith G.E., Younkin L.H., Petersen R.C., and Younkin S.G. Association of low plasma Abeta42/Abeta40 ratios with increased imminent risk for mild cognitive impairment and Alzheimer disease. Arch. Neurol. 64 (2007) 354-362
30. Hampel H., Burger K., Teipel S.J., Bokde A.L., Zetterberg H., and Blennow K. Core candidate neurochemical and imaging biomarkers of Alzheimer's disease. Alzheimers Dement. 4 (2008) 38-48
31. Hansson O., Zetterberg H., Buchhave P., Andreasson U., Londos E., Minthon L., and Blennow K. Prediction of Alzheimer's disease using the CSF Abeta42/Abeta40 ratio in patients with mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 23 (2007) 316-320
32. Hansson O., Zetterberg H., Vanmechelen E., Vanderstichele H., Andreasson U., Londos E., Wallin A., Minthon L., and Blennow K. Evaluation of plasma Abeta(40) and Abeta(42) as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment. Neurobiol. Aging (2008) doi:10.1016/j.neurobiolaging.2008.03.027
33. Hye A., Lynham S., Thambisetty M., Causevic M., Campbell J., Byers H.L., Hooper C., Rijsdijk F., Tabrizi S.J., Banner S., Shaw C.E., Foy C., Poppe M., Archer N., Hamilton G., Powell J., Brown R.G., Sham P., Ward M., and Lovestone S. Proteome-based plasma biomarkers for Alzheimer's disease. Brain 129 (2006) 3042-3050
34. Irizarry M.C., Yao Y., Hyman B.T., Growdon J.H., and Pratico D. Plasma F2A isoprostane levels in Alzheimer's and Parkinson's disease. Neurodegener. Dis. 4 (2007) 403-405
35. Kawarabayashi T., and Shoji M. Plasma biomarkers of Alzheimer's disease. Curr. Opin. Psychiatry 21 (2008) 260-267
36. Kelley, B.J., Petersen, R.C., 2007. Alzheimer's disease and mild cognitive impairment. Neurol Clin. 25, 577-609, v.
37. Kidd P.M. Alzheimer's disease, amnestic mild cognitive impairment, and age-associated memory impairment: current understanding and progress toward integrative prevention. Altern. Med. Rev. 13 (2008) 85-115
38. Koldamova R.P., Letterou I.M., Lefterova M.I., and Lazo J.S. Apolipoprotein A-I directly interacts with amyloid precursor protein and inhibits A beta aggregation and toxicity. Biochemistry 40 (2001) 3553-3560
39. Korolainen M.A., and Pirttila T. Cerebrospinal fluid, serum and plasma protein oxidation in Alzheimer's disease. Acta Neurol. Scand. 119 (2009) 32-38
40. Kosaka T., Imagawa M., Seki K., Arai H., Sasaki H., Tsuji S., Asami-Odaka A., Fukushima T., Imai K., and Iwatsubo T. The beta APP717 Alzheimer mutation increases the percentage of plasma amyloid-beta protein ending at A beta42(43). Neurology 48 (1997) 741-745
41. Kulminski A.M., Ukraintseva S.V., Arbeev K.G., Manton K.G., Oshima J., Martin G.M., Il'yasova D., and Yashin A.I. Health-protective and adverse effects of the apolipoprotein E epsilon2 allele in older men. J. Am. Geriatr. Soc. 56 (2008) 478-483
42. Lee P.H., Bang O.Y., Hwang E.M., Lee J.S., Joo U.S., Mook-Jung I., and Huh K. Circulating beta amyloid protein is elevated in patients with acute ischemic stroke. J. Neural. Transm. 112 (2005) 1371-1379
43. Liao P.-c., Yu L., Kuo C.-C., Lin C., and Kuo Y.-M. Proteomics analysis of plasma for potential biomarkers in the diagnosis of Alzheimer's disease. Proteomics - Clinical Applications 1 (2007) 506-512
44. Liu H.C., Hu C.J., Chang J.G., Sung S.M., Lee L.S., Yuan R.Y., and Leu S.J. Proteomic identification of lower apolipoprotein A-I in Alzheimer's disease. Dement. Geriatr. Cogn. Disord. 21 (2006) 155-161
45. Locascio J.J., Fukumoto H., Yap L., Bottiglieri T., Growdon J.H., Hyman B.T., and Irizarry M.C. Plasma amyloid beta-protein and C-reactive protein in relation to the rate of progression of Alzheimer disease. Arch. Neurol. 65 (2008) 776-785
46. Lopez M.F., Mikulskis A., Kuzdzal S., Bennett D.A., Kelly J., Golenko E., DiCesare J., Denoyer E., Patton W.F., Ediger R., Sapp L., Ziegert T., Lynch C., Kramer S., Whiteley G.R., Wall M.R., Mannion D.P., Della Cioppa G., Rakitan J.S., and Wolfe G.M. High-resolution serum proteomic profiling of Alzheimer disease samples reveals disease-specific, carrier-protein-bound mass signatures. Clin. Chem. 51 (2005) 1946-1954
47. Lopez O.L., Kuller L.H., Mehta P.D., Becker J.T., Gach H.M., Sweet R.A., Chang Y.F., Tracy R., and DeKosky S.T. Plasma amyloid levels and the risk of AD in normal subjects in the Cardiovascular Health Study. Neurology 70 (2008) 1664-1671
48. Lovell M.A., and Markesbery W.R. Oxidative damage in mild cognitive impairment and early Alzheimer's disease. J. Neurosci. Res. 85 (2007) 3036-3040
49. Maler J.M., Klafki H.W., Paul S., Spitzer P., Groemer T.W., Henkel A.W., Esselmann H., Lewczuk P., Kornhuber J., and Wiltfang J. Urea-based two-dimensional electrophoresis of beta-amyloid peptides in human plasma: evidence for novel Abeta species. Proteomics 7 (2007) 3815-3820
50. Mayeux R., Honig L.S., Tang M.X., Manly J., Stern Y., Schupf N., and Mehta P.D. Plasma A[beta]40 and A[beta]42 and Alzheimer's disease: relation to age, mortality, and risk. Neurology 61 (2003) 1185-1190
51. Mehta P.D., Pirttila T., Mehta S.P., Sersen E.A., Aisen P.S., and Wisniewski H.M. Plasma and cerebrospinal fluid levels of amyloid beta proteins 1-40 and 1-42 in Alzheimer disease. Arch. Neurol. 57 (2000) 100-105
52. Mhyre T.R., Loy R., Tariot P.N., Profenno L.A., Maguire-Zeiss K.A., Zhang D., Coleman P.D., and Federoff H.J. Proteomic analysis of peripheral leukocytes in Alzheimer's disease patients treated with divalproex sodium. Neurobiol. Aging 29 (2008) 1631-1643
53. Montine T.J., Quinn J.F., Milatovic D., Silbert L.C., Dang T., Sanchez S., Terry E., Roberts II L.J., Kaye J.A., and Morrow J.D. Peripheral F2-isoprostanes and F4-neuroprostanes are not increased in Alzheimer's disease. Ann. Neurol. 52 (2002) 175-179
54. Montine T.J., Quinn J., Kaye J., and Morrow J.D. F(2)-isoprostanes as biomarkers of late-onset Alzheimer's disease. J. Mol. Neurosci. 33 (2007) 114-119
55. Nielsen H.M., Minthon L., Londos E., Blennow K., Miranda E., Perez J., Crowther D.C., Lomas D.A., and Janciauskiene S.M. Plasma and CSF serpins in Alzheimer disease and dementia with Lewy bodies. Neurology 69 (2007) 1569-1579
56. Patterson C., Feightner J.W., Garcia A., Hsiung G.Y., MacKnight C., and Sadovnick A.D. Diagnosis and treatment of dementia: 1. Risk assessment and primary prevention of Alzheimer disease. CMAJ 178 (2008) 548-556
57. Perry G., Friedman R., Shaw G., and Chau V. Ubiquitin is detected in neurofibrillary tangles and senile plaque neurites of Alzheimer disease brains. Proc. Natl. Acad. Sci. U. S. A. 84 (1987) 3033-3036
58. Petersen R.C., Smith G.E., Ivnik R.J., Tangalos E.G., Schaid D.J., Thibodeau S.N., Kokmen E., Waring S.C., and Kurland L.T. Apolipoprotein E status as a predictor of the development of Alzheimer's disease in memory-impaired individuals. JAMA 273 (1995) 1274-1278
59. Petersen R.C., Doody R., Kurz A., Mohs R.C., Morris J.C., Rabins P.V., Ritchie K., Rossor M., Thal L., and Winblad B. Current concepts in mild cognitive impairment. Arch. Neurol. 58 (2001) 1985-1992
60. Poljak A., Sachdev P., and Smythe G.A. Causes and diagnosis of Alzheimer's disease: a proteomics approach. Current Proteomics (2006) 81-112
61. Pomara N., Willoughby L.M., Sidtis J.J., and Mehta P.D. Selective reductions in plasma Abeta 1-42 in healthy elderly subjects during longitudinal follow-up: a preliminary report. Am. J. Geriatr. Psychiatry 13 (2005) 914-917
62. Porsteinsson A.P., Tariot P.N., Jakimovich L.J., Kowalski N., Holt C., Erb R., and Cox C. Valproate therapy for agitation in dementia: open-label extension of a double-blind trial. Am. J. Geriatr. Psychiatry. 11 (2003) 434-440
63. Potempa J., Korzus E., and Travis J. The serpin superfamily of proteinase inhibitors: structure, function, and regulation. J. Biol. Chem. 269 (1994) 15957-15960
64. Pratico D. Peripheral biomarkers of oxidative damage in Alzheimer's disease: the road ahead. Neurobiol. Aging 26 (2005) 581-583
65. Pratico D., Clark C.M., Lee V.M., Trojanowski J.Q., Rokach J., and FitzGerald G.A. Increased 8,12-iso-iPF2alpha-VI in Alzheimer's disease: correlation of a noninvasive index of lipid peroxidation with disease severity. Ann. Neurol. 48 (2000) 809-812
66. Pratico D., Clark C.M., Liun F., Rokach J., Lee V.Y., and Trojanowski J.Q. Increase of brain oxidative stress in mild cognitive impairment: a possible predictor of Alzheimer disease. Arch. Neurol. 59 (2002) 972-976
67. Quinn J.F., Montine K.S., Moore M., Morrow J.D., Kaye J.A., and Montine T.J. Suppression of longitudinal increase in CSF F2-isoprostanes in Alzheimer's disease. J. Alzheimers Dis. 6 (2004) 93-97
68. Ramakers I.H., Visser P.J., Aalten P., Bekers O., Sleegers K., van Broeckhoven C.L., Jolles J., and Verhey F.R. The association between APOE genotype and memory dysfunction in subjects with mild cognitive impairment is related to age and alzheimer pathology. Dement. Geriatr. Cogn. Disord. 26 (2008) 101-108
69. Ray S., Britschgi M., Herbert C., Takeda-Uchimura Y., Boxer A., Blennow K., Friedman L.F., Galasko D.R., Jutel M., Karydas A., Kaye J.A., Leszek J., Miller B.L., Minthon L., Quinn J.F., Rabinovici G.D., Robinson W.H., Sabbagh M.N., So Y.T., Sparks D.L., Tabaton M., Tinklenberg J., Yesavage J.A., Tibshirani R., and Wyss-Coray T. Classification and prediction of clinical Alzheimer's diagnosis based on plasma signaling proteins. Nat. Med. 13 (2007) 1359-1362
70. Reitz C., Tang M.X., Manly J., Schupf N., Mayeux R., and Luchsinger J.A. Plasma lipid levels in the elderly are not associated with the risk of mild cognitive impairment. Dement. Geriatr. Cogn. Disord. 25 (2008) 232-237
71. Rountree S.D., Waring S.C., Chan W.C., Lupo P.J., Darby E.J., and Doody R.S. Importance of subtle amnestic and nonamnestic deficits in mild cognitive impairment: prognosis and conversion to dementia. Dement. Geriatr. Cogn. Disord. 24 (2007) 476-482
72. Sachdev P.S. Homocysteine and brain atrophy. Prog. Neuropsychopharmacol. Biol. Psychiatry. 29 (2005) 1152-1161
73. Sando S.B., Melquist S., Cannon A., Hutton M.L., Sletvold O., Saltvedt I., White L.R., Lydersen S., and Aasly J.O. APOE epsilon 4 lowers age at onset and is a high risk factor for Alzheimer's disease; a case control study from central Norway. BMC Neurol. 8 (2008) 9
74. Saunders A.M., Strittmatter W.J., Schmechel D., George-Hyslop P.H., Pericak-Vance M.A., Joo S.H., Rosi B.L., Gusella J.F., Crapper-MacLachlan D.R., Alberts M.J., et al. Association of apolipoprotein E allele epsilon 4 with late-onset familial and sporadic Alzheimer's disease. Neurology 43 (1993) 1467-1472
75. Schmidt R., Schmidt H., Curb J.D., Masaki K., White L.R., and Launer L.J. Early inflammation and dementia: a 25-year follow-up of the Honolulu-Asia Aging Study. Ann. Neurol. 52 (2002) 168-174
76. Schuitemaker A., Dik M.G., Veerhuis R., Scheltens P., Schoonenboom N.S., Hack C.E., Blankenstein M.A., and Jonker C. Inflammatory markers in AD and MCI patients with different biomarker profiles. Neurobiol. Aging 30 11 (2008) 1885-1889
77. Selhub J., Jacques P.F., Wilson P.W., Rush D., and Rosenberg I.H. Vitamin status and intake as primary determinants of homocysteinemia in an elderly population. JAMA 270 (1993) 2693-2698
78. Selkoe D.J. Normal and abnormal biology of the beta-amyloid precursor protein. Annu. Rev. Neurosci. 17 (1994) 489-517
79. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 53 (1994) 438-447
80. Seshadri S. Elevated plasma homocysteine levels: risk factor or risk marker for the development of dementia and Alzheimer's disease?. J. Alzheimers Dis. 9 (2006) 393-398
81. Seshadri S., Beiser A., Selhub J., Jacques P.F., Rosenberg I.H., D'Agostino R.B., Wilson P.W., and Wolf P.A. Plasma homocysteine as a risk factor for dementia and Alzheimer's disease. N. Engl. J. Med. 346 (2002) 476-483
82. Sihlbom C., Davidsson P., Sjogren M., Wahlund L.O., and Nilsson C.L. Structural and quantitative comparison of cerebrospinal fluid glycoproteins in Alzheimer's disease patients and healthy individuals. Neurochem. Res. 33 (2008) 1332-1340
83. Simonsen A.H., McGuire J., Hansson O., Zetterberg H., Podust V.N., Davies H.A., Waldemar G., Minthon L., and Blennow K. Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment. Arch. Neurol. 64 (2007) 366-370
84. Sival R.C., Haffmans P.M., Jansen P.A., Duursma S.A., and Eikelenboom P. Sodium valproate in the treatment of aggressive behavior in patients with dementia-a randomized placebo controlled clinical trial. Int. J. Geriatr. Psychiatry 17 (2002) 579-585
85. Sjogren M., Minthon L., Davidsson P., Granerus A.K., Clarberg A., Vanderstichele H., Vanmechelen E., Wallin A., and Blennow K. CSF levels of tau, beta-amyloid(1-42) and GAP-43 in frontotemporal dementia, other types of dementia and normal aging. J. Neural. Transm. 107 (2000) 563-579
86. Smach M.A., Charfeddine B., Lammouchi T., Harrabi I., Ben Othman L., Dridi H., Bennamou S., and Limem K. CSF beta-amyloid 1-42 and tau in Tunisian patients with Alzheimer's disease: the effect of APOE epsilon4 allele. Neurosci. Lett. 440 (2008) 145-149
87. Snowdon D.A., Kemper S.J., Mortimer J.A., Greiner L.H., Wekstein D.R., and Markesbery W.R. Linguistic ability in early life and cognitive function and Alzheimer's disease in late life. Findings from the Nun Study. JAMA 275 (1996) 528-532
88. Solfrizzi V., D'Introno A., Colacicco A.M., Capurso C., Todarello O., Pellicani V., Capurso S.A., Pietrarossa G., Santamato V., Capurso A., and Panza F. Circulating biomarkers of cognitive decline and dementia. Clin. Chim. Acta 364 (2006) 91-112
89. Solomon A., Kareholt I., Ngandu T., Winblad B., Nissinen A., Tuomilehto J., Soininen H., and Kivipelto M. Serum cholesterol changes after midlife and late-life cognition: twenty-one-year follow-up study. Neurology 68 (2007) 751-756
90. Sorli J.V., Corella D., Frances F., Ramirez J.B., Gonzalez J.I., Guillen M., and Portoles O. The effect of the APOE polymorphism on HDL-C concentrations depends on the cholesterol ester transfer protein gene variation in a Southern European population. Clin. Chim. Acta 366 (2006) 196-203
91. Strohmeyer R., Shen Y., and Rogers J. Detection of complement alternative pathway mRNA and proteins in the Alzheimer's disease brain. Brain Res. Mol. Brain Res. 81 (2000) 7-18
92. Sunderland T., Linker G., Mirza N., Putnam K.T., Friedman D.L., Kimmel L.H., Bergeson J., Manetti G.J., Zimmermann M., Tang B., Bartko J.J., and Cohen R.M. Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease. JAMA 289 (2003) 2094-2103
93. Tamaoka A., Fukushima T., Sawamura N., Ishikawa K., Oguni E., Komatsuzaki Y., and Shoji S. Amyloid beta protein in plasma from patients with sporadic Alzheimer's disease. J. Neurol. Sci. 141 (1996) 65-68
94. Tang B.L., and Kumar R. Biomarkers of mild cognitive impairment and Alzheimer's disease. Ann. Acad. Med. Singapore 37 (2008) 406-410
95. Tariot P.N., Raman R., Jakimovich L., Schneider L., Porsteinsson A., Thomas R., Mintzer J., Brenner R., Schafer K., and Thal L. Divalproex sodium in nursing home residents with possible or probable Alzheimer disease complicated by agitation: a randomized, controlled trial. Am. J. Geriatr. Psychiatry 13 (2005) 942-949
96. Thambisetty M., Hye A., Foy C., Daly E., Glover A., Cooper A., Simmons A., Murphy D., and Lovestone S. Proteome-based identification of plasma proteins associated with hippocampal metabolism in early Alzheimer's disease. J. Neurol. 255 (2008) 1712-1720
97. Tucker K.L., Qiao N., Scott T., Rosenberg I., and Spiro III A. High homocysteine and low B vitamins predict cognitive decline in aging men: the Veterans Affairs Normative Aging Study. Am. J. Clin. Nutr. 82 (2005) 627-635
98. van Dijk E.J., Prins N.D., Vermeer S.E., Hofman A., van Duijn C.M., Koudstaal P.J., and Breteler M.M. Plasma amyloid beta, apolipoprotein E, lacunar infarcts, and white matter lesions. Ann. Neurol. 55 (2004) 570-575
99. van Oijen M., Hofman A., Soares H.D., Koudstaal P.J., and Breteler M.M. Plasma Abeta(1-40) and Abeta(1-42) and the risk of dementia: a prospective case-cohort study. Lancet Neurol. 5 (2006) 655-660
100. Veerhuis R., Van Breemen M.J., Hoozemans J.M., Morbin M., Ouladhadj J., Tagliavini F., and Eikelenboom P. Amyloid beta plaque-associated proteins C1q and SAP enhance the Abeta1-42 peptide-induced cytokine secretion by adult human microglia in vitro. Acta Neuropathol. 105 (2003) 135-144
101. Wilson R.S., Bienias J.L., Berry-Kravis E., Evans D.A., and Bennett D.A. The apolipoprotein E epsilon 2 allele and decline in episodic memory. J. Neurol. Neurosurg. Psychiatry 73 (2002) 672-677
102. Yaffe K., Lindquist K., Penninx B.W., Simonsick E.M., Pahor M., Kritchevsky S., Launer L., Kuller L., Rubin S., and Harris T. Inflammatory markers and cognition in well-functioning African-American and white elders. Neurology 61 (2003) 76-80
103. Yasojima K., Schwab C., McGeer E.G., and McGeer P.L. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res. 887 (2000) 80-89
104. Younkin S.G. Evidence that A beta 42 is the real culprit in Alzheimer's disease. Ann. Neurol. 37 (1995) 287-288
105. Yu H.L., Chertkow H.M., Bergman H., and Schipper H.M. Aberrant profiles of native and oxidized glycoproteins in Alzheimer plasma. Proteomics 3 (2003) 2240-2248
106. Zhang R., Barker L., Pinchev D., Marshall J., Rasamoelisolo M., Smith C., Kupchak P., Kireeva I., Ingratta L., and Jackowski G. Mining biomarkers in human sera using proteomic tools. Proteomics 4 (2004) 244-256
107. Zlokovic B.V. Clearing amyloid through the blood-brain barrier. J. Neurochem. 89 (2004) 807-811